Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 ONO-7057 in relapsed/refractory multiple myeloma
jRCT2080221974Phase 1Completed
- Sponsor
- Ono Pharmaceutical
- Start
- Dec 2012
- Modality
- Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, Reversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of carfilzomib in multiple myeloma (MM) (3 arms), sponsored by Ono Pharmaceutical. Primary endpoints: Safety and tolerability of ONO-7057 and Pharmacokinetics of ONO-7057. Started Dec 2012; status: completed.
02
Drugs
carfilzomib
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on jRCT2080221974.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080221974.